| Filed On | Filing |
|---|---|
| 20 Aug 2026 |
8-K/A: Material Modification to Rights of Security Holders
The previously disclosed Certificate will become effective at 12:01 am New York time on Thursday, August 24, 2026, with the Company’s common stock to begin trading on The Nasdaq Stock Market LLC on a split-adjusted basis at market open o... |
| 06 Apr 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The total number of shares of common stock of the Company underling all Repriced Options is 2,458,158 shares. |
| 01 Sep 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In accordance with the closing of the Merger, Andrew Schwab and Paul Grayson were appointed to the Board. |
| 27 Mar 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On February 16, 2023, Skye Bioscience, Inc. (the "Company") filed a Current Report on Form 8-K (the "Initial 8-K") to report the appointment of Dr. Deborah Charych, Ph.D. as a director of the Company's Board of Directors (the "Board"). A... |
| 20 Jan 2017 | 8-K/A: Financial Statements and Exhibits |
| 18 Nov 2014 | 8-K/A: Changes in Registrant's Certifying Accountant |
Loading...
